Janus Kinases in Leukemia [PDF]
Cancers, 2021 Janus kinases (JAKs) transduce signals from dozens of extracellular cytokines and function as critical regulators of cell growth, differentiation, gene expression, and immune responses. Deregulation of JAK/STAT signaling is a central component in several human diseases including various types of leukemia and other malignancies and autoimmune diseases ...
Teemu Haikarainen +2 more
exaly +10 more sources
Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases [PDF]
Pharmaceuticals, 2019 In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK).
Annie Mayence +1 more
exaly +6 more sources
Parthenolide Inhibits STAT3 Signaling by Covalently Targeting Janus Kinases [PDF]
Molecules, 2018 Aberrant activations of the STAT3 (signal transducer and activator of transcription 3) signaling pathway are associated with cancer and inflammatory diseases.
Man Liu +5 more
doaj +4 more sources
Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes [PDF]
Biomedicines, 2021 Crosstalk between synovial fibroblasts (SF) and immune cells plays a central role in the development of rheumatoid arthritis (RA). Janus kinase inhibitors (JAKi) have proven efficacy in the treatment of RA, although clinical responses are heterogeneous ...
Theresa Tretter +2 more
exaly +4 more sources
Molecular dissection of Janus kinases as drug targets for inflammatory diseases [PDF]
Frontiers in Immunology, 2022 The Janus kinase (JAK) family enzymes are non-receptor tyrosine kinases that phosphorylate cytokine receptors and signal transducer and activator of transcription (STAT) proteins in the JAK-STAT signaling pathway.
Sunghark Kwon
doaj +2 more sources
In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones [PDF]
Molecules, 2023 Janus kinases (JAKs) are involved in numerous cellular signaling processes related to immune cell functions. JAK2 and JAK3 are associated with the pathogenesis of leukemia and common lymphoid-derived illnesses.
Kamonpan Sanachai +8 more
doaj +2 more sources
Revisiting Janus kinases as molecular drug targets for rheumatic diseases [PDF]
Frontiers in MedicineJanus kinase (JAK) family members, as upstream regulators, phosphorylate not only themselves but also cytokine receptors and signal transducer and activator of transcription (STAT) proteins in the JAK-STAT signaling pathway.
Sunghark Kwon, Sunghark Kwon
doaj +2 more sources
Evaluation of immunohistochemical and gene expression of Janus kinase 1 and Janus kinase 3 in the skin of different clinical types of mycosis fungoides patients - Part II: reverse transcriptase-polymerase chain reaction [PDF]
Anais Brasileiros de DermatologiaBackground Mycosis Fungoides (MF) is the commonest type of primary cutaneous T-Cell lymphomas representing about 50% of all lymphomas arising primarily in the skin. Janus kinases are non-receptor intracellular tyrosine kinases that play an important role
Heba Saed El-Amawy +3 more
doaj +3 more sources
Janus kinases in immune cell signaling [PDF]
Immunological Reviews, 2009 Summary: The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non‐receptor protein tyrosine kinases. They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.
Kamran Ghoreschi +2 more
exaly +3 more sources
Evaluation of immunohistochemical and gene expression of Janus kinase 1 and Janus kinase 3 in the skin of different clinical types of mycosis fungoides patients - Part I [PDF]
Anais Brasileiros de DermatologiaBackground Mycosis fungoides is the commonest type of cutaneous T-Cell lymphoma. Janus kinases are intracellular tyrosine kinases that have recently been proven to have a crucial role in the pathogenesis and progression of several dermatological and ...
Heba Saed El-Amawy +3 more
doaj +3 more sources